FebriDx for C-reactive protein and myxovirus resistance protein A testing. NICE Medtech Innovation briefing
FebriDx for C-reactive protein and myxovirus resistance protein A testing. NICE Medtech Innovation briefing
• The technology described in this briefing is FebriDx. It is a rapid dual marker immunoassay test.
The test detects raised levels of C-reactive protein (CRP) and myxovirus resistance protein A
(MxA) in peripheral whole blood. The test is done at the point of care and gives results in
10 minutes.
• The innovative aspects are that the FebriDx test measures MxA, a marker for viral infection, as
well as CRP. This helps clinicians to differentiate between bacterial and viral respiratory tract
infections.
• The intended place in therapy would be in primary or secondary care, to help guide the
appropriate use of antibiotics for people with acute febrile respiratory tract infections. It could
also help with early detection of viral infections, such as COVID-19.
Clark, Tristan
712ec18e-613c-45df-a013-c8a22834e14f
26 August 2020
Clark, Tristan
712ec18e-613c-45df-a013-c8a22834e14f
Clark, Tristan
(2020)
FebriDx for C-reactive protein and myxovirus resistance protein A testing. NICE Medtech Innovation briefing.
15 pp
.
Record type:
Conference or Workshop Item
(Paper)
Abstract
• The technology described in this briefing is FebriDx. It is a rapid dual marker immunoassay test.
The test detects raised levels of C-reactive protein (CRP) and myxovirus resistance protein A
(MxA) in peripheral whole blood. The test is done at the point of care and gives results in
10 minutes.
• The innovative aspects are that the FebriDx test measures MxA, a marker for viral infection, as
well as CRP. This helps clinicians to differentiate between bacterial and viral respiratory tract
infections.
• The intended place in therapy would be in primary or secondary care, to help guide the
appropriate use of antibiotics for people with acute febrile respiratory tract infections. It could
also help with early detection of viral infections, such as COVID-19.
Text
NICE Medtech innovation briefing FebriDx 2020
- Version of Record
Restricted to Repository staff only
Request a copy
More information
Published date: 26 August 2020
Identifiers
Local EPrints ID: 449303
URI: http://eprints.soton.ac.uk/id/eprint/449303
PURE UUID: 1173b53e-385b-4c02-accc-5fdcf30ea0ca
Catalogue record
Date deposited: 24 May 2021 16:30
Last modified: 17 Mar 2024 03:34
Export record
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics
